Prediction of long-term treatment outcome in HCV following 24 day PEG-IFN alpha-2b therapy using population pharmacokinetic-pharmacodynamic mixture modeling and classification analysis
From MaRDI portal
(Redirected from Publication:739328)
Recommendations
- Towards prediction of HCV therapy efficiency
- Modeling the dynamics of hepatitis C virus with combined antiviral drug therapy: interferon and ribavirin
- Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor
- Modeling the impact of hepatitis C viral clearance on end-stage liver disease in an HIV co-infected cohort with targeted maximum likelihood estimation
- Dynamics of hepatitis C under optimal therapy and sampling based analysis
- Machine learning for mathematical models of HCV kinetics during antiviral therapy
- Modelling hepatotoxicity and antiretroviral therapeutic effect in HIV/HBV coinfection
- Dynamic analysis for delayed HCV infection in \textit{VIVO} with anti-retro viral treatment
- Feasibility of parameter estimation in hepatitis C viral dynamics models
- Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy
Cited in
(5)- Using machine learning algorithms to predict hepatitis B surface antigen seroclearance
- Modeling of viral dynamics after liver transplantation in patients with chronic hepatitis B and D
- Towards prediction of HCV therapy efficiency
- vRNA structured population model for Hepatitis C virus dynamics
- Evaluating treatment of hepatitis C for hemolytic anemia management
This page was built for publication: Prediction of long-term treatment outcome in HCV following 24 day PEG-IFN alpha-2b therapy using population pharmacokinetic-pharmacodynamic mixture modeling and classification analysis
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q739328)
